...
首页> 外文期刊>Critical care : >Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study
【24h】

Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study

机译:危重患者接受高剂量静脉注射大肠菌素甲磺酸盐和/或其他肾毒性抗生素的急性肾损伤的危险因素:一项回顾性队列研究

获取原文

摘要

IntroductionUse of colistin methanesulfonate (CMS) was abandoned in the 1970s because of excessive nephrotoxicity, but it has been reintroduced as a last-resort treatment for extensively drug-resistant infections caused by gram-negative bacteria (Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumonia). We conducted a retrospective cohort study to evaluate risk factors for new-onset acute kidney injury (AKI) in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics.MethodsThe cohort consisted of 279 adults admitted to two general ICUs in teaching hospitals between 1 April 2009 and 30 June 2011 with 1) no evidence on admission of acute or chronic kidney disease; and 2) treatment for more than seven days with CMS and/or other nephrotoxic antimicrobials (NAs, that is, aminoglycosides, glycopeptides). Logistic regression analysis was used to identify risk factors associated with this outcome.ResultsThe 279 cases that met the inclusion criteria included 147 patients treated with CMS, alone (n = 90) or with NAs (n = 57), and 132 treated with NAs alone. The 111 (40%) who developed AKI were significantly older and had significantly higher Simplified Acute Physiology Score II (SAPS II) scores than those who did not develop AKI, but rates of hypertension, diabetes mellitus and congestive heart failure were similar in the two groups. The final logistic regression model showed that in the 147 patients who received CMS alone or with NAs, onset of AKI during the ICU stay was associated with septic shock and with SAPS II scores ≥43. Similar results were obtained in the 222 patients treated with CMS alone or NAs alone.ConclusionsIn severely ill ICU patients without pre-existing renal disease who receive CMS high-dose for more than seven days, CMS therapy does not appear to be a risk factor for this outcome. Instead, the development of AKI was strongly correlated with the presence of septic shock and with the severity of the patients as reflected by the SAPS II score.
机译:简介1970年代,由于过度的肾毒性而放弃使用大肠菌素甲磺酸盐(CMS),但已被重新引入作为革兰氏阴性细菌(鲍曼不动杆菌,铜绿假单胞菌,肺炎克雷伯氏菌)引起的广泛耐药性感染的最后手段。 。我们进行了一项回顾性队列研究,以评估接受高剂量静脉注射大肠菌素甲磺酸盐和/或其他肾毒性抗生素的危重患者的新发急性肾损伤(AKI)的危险因素。在2009年4月1日至2011年6月30日之间对医院进行教学,其中1)没有任何有关接受急性或慢性肾脏疾病的证据; 2)用CMS和/或其他肾毒性抗菌剂(NAs,即氨基糖苷,糖肽)治疗7天以上。结果采用Logistic回归分析来确定与此结果相关的危险因素。结果符合纳入标准的279例患者包括147例接受CMS单独治疗(n = 90)或NAs(n = 57)和132例单独接受NAs的患者。发生AKI的111名(40%)年龄明显偏大,并且比未发生AKI的那些具有更高的简化急性生理学II级(SAPS II)得分,但两者的高血压,糖尿病和充血性心力衰竭的发生率相似组。最终的logistic回归模型显示,在147例单独接受CMS或NAs的患者中,ICU住院期间AKI的发作与败血性休克和SAPS II评分≥43有关。在222例仅接受CMS或仅接受NAs治疗的患者中也获得了相似的结果。结论对于重症ICU患者,既往没有肾脏疾病的重症监护病房,接受CMS高剂量治疗超过7天,CMS治疗似乎不是导致CMS的危险因素。这个结果。取而代之的是,AKI的发生与败血性休克的存在以及患者严重程度密切相关,如SAPS II评分所反映。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号